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Background: Neoplastic meningitis (NM) is a devastating neuro-
logical complication of cancer that needs to be diagnosed in the
early stages of disease. Polymerase chain reaction detection of
epithelial growth factor receptor (EGFR) mutations in cerebrospinal
fluid (CSF), which are predictive markers for EGFR tyrosine kinase
inhibitor therapy in lung cancer, might be important to diagnose and
to treat NM in patients with lung cancer. In this study, we attempted
to detect EGFR mutations in CSF and to compare EGFR status
between CSF and primary or metastatic lesions in patients with lung
adenocarcinoma suspected of NM.
Methods: Twenty-nine patients with lung adenocarcinoma sus-
pected of having NM underwent lumbar puncture. EGFR status of
CSF was analyzed by direct DNA sequencing. EGFR mutations of
primary or metastatic lesions (lymph nodes and bones) were ana-
lyzed in 20 cases.
Results: EGFR mutations were detected in CSF of 13 (45%) of 29
patients. In 5 (31%) of 16 patients with negative CSF cytology,
EGFR mutations were detected. In four patients, EGFR mutations
were shown in CSF, but not in primary or metastatic lesions.
Conversely, in two patients, EGFR mutations were shown in pri-
mary or metastatic lesions, but not in CSF despite positive CSF
cytology.
Conclusions: EGFR mutations, suggesting the existence of malig-
nant cells, were detected in CSF, even in patients with non-small cell
lung cancer with negative cytological results. EGFR mutations in
CSF do not always reflect the same status as in primary or metastatic
lesions.
Key Words: EGFR mutation, Cerebrospinal fluid, Lung cancer,
Neoplastic meningitis.
(J Thorac Oncol. 2011;6: 1215–1220)
Neoplastic meningitis (NM) is a devastating neurologicalcomplication of cancer that is clinically diagnosed in 4
to 15% of patients with solid tumors, 5 to 15% of patients
with leukemia and lymphoma, and 1 to 2% of patients with
primary brain tumors.1 Nevertheless, NM remains underdi-
agnosed, considering postmortem incidence of the disease.2
Along with the diagnostic and therapeutic advancements,
malignant infiltration of the leptomeninges by systemic can-
cer is being recognized with increasing frequency. Leptomen-
ingeal metastasis of malignant cells is associated with high
morbidity and mortality rates. Most untreated patients die
within 1 to 9 weeks (median 3 weeks) as a result of neuro-
logical disease and tumor progression.3 Although fixed neu-
rological defects rarely improve with treatment, the progres-
sion of neurological deterioration may be halted in some
patients, and median survival can be increased to 4 to 6
months.1 Ideally, NM should be diagnosed in the early stages
of disease to prevent progression of disabling neurological
deficits. The most useful laboratory test in the diagnosis of
NM is a cerebrospinal fluid (CSF) examination. Cytological
detection of malignant cells in CSF is highly specific for NM,
but the sensitivity of the detection is 50 to 60% in patients
with autopsy-proven leptomeningeal tumors.4,5 CSF speci-
mens frequently contain so few morphologically recognizable
malignant cells that even the most experienced cytologists are
unable to render a definitive diagnosis.
The exquisite sensitivity of polymerase chain reaction
(PCR) techniques offers an opportunity for tumor diagnosis
based on the detection of tumor-derived DNA present in CSF.
PCR techniques require that tumor-derived DNA be recog-
nizably different from nontumor DNA. Previous studies
showed the presence of oncogene amplification (HER-2/neu
and epithelial growth factor receptor [EGFR]), p53 gene
mutation, or clonal rearrangements of the immunoglobulin
gene to demonstrate the presence of tumor-derived DNA in
CSF.6–8 Therefore, detection of tumor-specific genes by PCR
may be sensitive and useful for detecting malignant cells in
CSF, even if cytological investigation of CSF cannot detect
malignant cells.
Lung cancer is the leading cause of cancer-related death
despite intensive treatment. In April 2004, two groups of
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researchers in Boston and subsequently a group in New York
reported that activating mutations of the EGFR gene were
present in a subset of non-small cell lung cancer (NSCLC),
and that tumors with EGFR mutations are highly sensitive to
EGFR tyrosine kinase inhibitors (TKIs).9–11 Thereafter,
EGFR mutations were extensively investigated. The muta-
tions are predominantly found in patients with lung adeno-
carcinoma.12 The mutations consist of small, in-frame dele-
tions or substitutions clustered around the adenosine
triphosphate-binding site in exons 18 to 21 of the EGFR gene,
and approximately 90% of patients with EGFR mutations
have one of two major mutations.13 One is a 15-base pair
nucleotide in-frame deletion (E746 A750del) in exon 19, and
the other is a point mutation involving the replacement of
leucine with arginine at codon 858 (L858R) in exon 21. The
above-mentioned studies included genetic analyses of surgi-
cal tissues or biopsy specimens obtained from lungs, pleural
effusions, and metastatic lymph nodes.14–16
We propose that EGFR mutations might be a useful
target for PCR to detect cancer cells in CSF in patients with
lung cancer suspected of NM. In this study, we attempted to
detect EGFR mutations in CSF and to compare EGFR status
between CSF and primary or metastatic lesions.
PATIENTS AND METHODS
Patients
The study population consisted of 29 pathologically
confirmed patients with lung cancer who were suspected of
having NM from their clinical symptoms or from a magnetic
resonance imaging (MRI) of the brain or spinal cord. The
patients then underwent CSF examination for diagnosis.
Stage classification for lung cancer was based on the Inter-
national Union Against Cancer (UICC—7) tumor, node,
metastasis classification. Written informed consent was ob-
tained from each patient before the study.
CSF Sample Collection and DNA Extraction
Ten milliliters of CSF was aspirated by lumbar punc-
ture. Five milliliters of the sample was used for cytologic
examination and 4 ml to determine cell counts and biochem-
ical variables such as protein and glucose. The remainder was
used for DNA collection. Papanicolaou classification was
used for the interpretation of cytologic findings in CSF. Class
IV or V was considered as positive. For DNA collection, the
sample was immediately centrifuged at 1700g for 10 minutes,
and the supernatant was collected and stored at 20°C until
a DNA extract was taken. DNA was extracted from 100 l of
the collected supernatant using a DNA Extractor SP Kit
(Wako Pure Chemical Industries, Osaka, Japan) following the
manufacturer’s instructions.
Tumor Sample Collection and DNA Extraction
For analysis of EGFR status of tumors, DNA extraction
was performed in 20 of 29 patients. Seven tumor samples
were collected from the primary cancer by means of trans-
bronchial lung biopsy or needle aspiration, four were resected
operatively, and nine were collected from metastatic sites
(seven from lymph nodes and two from bone). Specimens
obtained by transbronchial lung biopsy or bone biopsy were
fixed with formalin and embedded in paraffin. Samples re-
sected operatively were stored at 80°C until a DNA extract
was taken. Materials from lung or lymph nodes obtained by
needle aspiration were washed in saline solution and stored at
20°C until a DNA extract was taken. Paraffin-embedded
samples were cut at a thickness of 5 m. Tumor cells were
dissected and extracted with xylene and ethanol to remove
paraffin. DNA was extracted from deparaffinized tissue, fro-
zen samples, or samples stored in saline solution using
QIAamp DNA Mini kit (Qiagen GmbH, Hilden, Germany)
following the manufacturer’s instructions.
Analysis of EGFR Gene Mutation
DNA concentration and purity were determined using
ultraviolet spectrophotometry (Nanodrop, Thermo Scientific,
Wilmington, DE). Exons 18 to 21 of the EGFR were sequen-
tially amplified by two rounds of PCR and subjected to direct
sequencing. The PCR primers for EGFR amplification were as
follows: Ex18-1stF: 5-CAAATGAGCTGGCAAGTGCCGT
GTC-3; Ex18-1stR: 5-CTGGAGTTTCCCAAACACTCAGT
GAAAC-3; Ex19-1stF: 5-GCAATATCAGCCTTAGGTG
CGGCTC-3; Ex19-1stR: 5-GACATAGAAAGTGAACATTT
AGGATGTGGAG-3; Ex20-1stF: 5-CTCTCCCACTGCAT
CTGTCACTTCAC-3; Ex20-1stR: 5-AGAACAGAGACAT
CAGACCACACTGAGC-3; Ex21-1stF: 5-CTAACGTTC
GCCAGCCATAAGTCC-3; Ex21-1stR: 5-TGCGAGCTCA
CCCAGAATGTCTGG-3; Ex18-2ndF: 5-CCGTGTCCTGG
CACCCAAGC-3; Ex18-2ndR: 5-CCCAAACACTCAGTG
AAACAAAGAGTAAAG-3; Ex19-2ndF: 5-GCAGCGGG
TTACATCTTCTTTC-3; Ex19-2ndR: 5-GTGAACATTTAGG
ATGTGGAGATGAGCAG-3; Ex20-2ndF: 5-TAAACGTC
CCTGTGCTAGGTCTTTTGC-3; Ex20-2ndR: 5-CATGCAG
ATGGGACAGGCACTGA-3; Ex21-2ndF: 5-CAGCCA
TAAGTCCTCGACGTGG-3; Ex21-2ndR: 5-CATCCTCCC
CTGCATGTGTTAAAC-3; WAVE-ex19-F: 5-TTGCCAGT-
TAACGTCTTCCTTCTCTCTC-3; and WAVE-ex19-R: 5-
ACATGAGAAAAGGTGGGCCTGAGGTT-3. The first PCR
was carried out in a total volume of 10 l containing 1/20 of the
extracted genomic DNA using 0.4 U of rTaq DNA polymerase
(TaKaRa Bio, Shiga, Japan). The initial denaturing step was at
96°C for 3 minutes, followed by 30 cycles of a denaturing step
at 95°C for 20 seconds, an annealing step at 58°C for 20
seconds, and an extension step at 72°C for 20 seconds, ending
with a final extension step at 72°C for 2 minutes. Nested PCR
was carried out in a total volume of 20 l, and the conditions
were identical to the first PCR, except for using 35 cycles instead
of 30 cycles. Denaturing high-performance liquid chromatogra-
phy analysis using a Transgenomic WAVE system with a
fragment collector (Transgenomic, Crewe, UK) was used to
scan for mutations in exon 19 of EGFR. All PCR fragments that
displayed an aberrant denaturing high-performance liquid chro-
matography chromatogram were sequenced to identify the un-
derlying nucleotide change. The PCR products were directly
sequenced by dye terminator sequencing (ABI BigDye Termi-
nator kit, v1.1; Applied Biosystems, Foster City, CA), purified
by ethanol precipitation, and separated by capillary electropho-
resis on an ABI 3730 DNA analyzer (Applied Biosystems).
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RESULTS
Patient Characteristics
Patient characteristics are listed in Table 1. A total of
29 patients with pathologically confirmed lung adenocarci-
noma suspected of having NM were analyzed for EGFR
mutation in CSF. Of the 29 patients, 15 were male (52%), and
24 had stage IV lung cancer. Their median age was 65 years
(range, 40–78 years). Eight patients had received no prior
treatment. Nine patients had neurological symptoms.
CSF Cytology
Class IV or V CSF cytology was found in 13 of 29
patients (45%; Table 2). In 9 of 13 patients, the number of
cells in CSF was within normal range (0–15/3 l; Table 2).
In 16 patients with negative CSF cytology, the number of
cells in CSF was within normal range, except for one case
with contamination of bleeding (Table 2).
EGFR Mutations of CSF Evaluated by Direct
DNA Sequencing
Using direct sequencing, EGFR mutations were de-
tected in CSF of 13 (45%) of 29 patients (Table 2). Nine cases
of in-frame deletions in exon 19 and four cases of amino acid
substitutions in exon 21 were detected. One patient who had
a L858R mutation in their CSF had another point mutation in
exon 21. Of 13 patients with class IV or V CSF cytology,
CSF EGFR mutations were detected in eight (62%). Of 16
patients with classes I to IIb CSF cytology, CSF EGFR
mutations were detected in five (31%). In all of these five
patients, the cell count in CSF was within normal range (1–15
cells/3 l).
Patient no. 25 had gait disturbance and vomiting at the
onset of NM. A MRI of the brain, CSF cytology results, and
direct sequencing results of the patient are shown (Figures
1A–C).
EGFR Mutations of Tumors Evaluated by Direct
DNA Sequencing
Of the 29 patients, 20 were analyzed for EGFR mutations
of primary or metastatic tumors by direct DNA sequencing
(Table 2). Samples were obtained from primary tumors in 11,
from metastatic lymph nodes in 7, and from metastatic bones in
2 patients. EGFR mutations were detected in 11 patients. Five
patients with in-frame deletions in exon 19, five patients with
amino acid substitutions in exon 21, and one patient with
amino acid substitutions in exon 18 were detected. One of the
four patients with amino acid substitutions in exon 21 had a
T790M mutation in exon 20 despite receiving no prior anti-
cancer therapy.
Comparison of the EGFR Mutations between
Tumors and CSF by Direct DNA Sequencing
Among the 13 patients with EGFR mutations in CSF,
there were 7 whose primary or metastatic tumor EGFR status
was analyzed by direct sequencing (Table 2). In two patients,
EGFR mutant locations of paired lesions between tumors and
CSF were accordant. Nevertheless, in four (56%) patients,
discordance in EGFR status of paired lesions between tumors
and CSF was detected. EGFR mutations were present only in
CSF, but not in tumors. All four patients received prior
chemotherapy. In the remaining patient, a L858R point
mutation was detected both in the primary tumor and the
CSF, but a T790M mutation, associated with resistance to
EGFR-TKI, was found only in the primary tumor, but not
in the CSF. This patient had no history of prior treatment
for lung cancer.
There were four patients who had EGFR mutant tumors
and were diagnosed as NM by positive CSF cytology. Two of
the four patients had wild-type EGFR status in their CSF.
DISCUSSION
Currently, three independent methods are used to diag-
nose NM: clinical presentation (i.e., neurological signs and
symptoms), CSF cytology, and central nervous system neu-
roradiographical examination with MRI.1,17 Each of these
methods is limited by either suboptimal sensitivity or speci-
ficity. For example, central nervous system signs and symp-
toms, which are the first indication of NM in the majority
(90%) of patients, are often subtle, unrecognized, and may
be difficult to distinguish from manifestations of the primary
disease or the neurological side effects of cancer treatment.1
The neuroradiographic method of choice, contrast-enhanced
MRI of the brain and spinal cord, is limited in detecting NM,
having a sensitivity of approximately 40 to 60% of cases.5
Synchronous intraparenchymal brain metastases are evident
in 11 to 31% of patients with NM.3 In some cases, it is
difficult to distinguish NM lesions from brain metastases by
MRI of the brain. In contrast, the often touted criterion
TABLE 1. Patient Characteristics
Number (n  29)
Sex
Male 15
Female 14
Age (yr)
Median 65
Range 40–78
Histology
Adenocarcinoma 29
Initial stage
IIA 1
IIIA 1
IIIB 3
IV 24
Prior treatment
None 8
Chemotherapy 11
TKI 5
Chemotherapy and TKI 2
Operation and chemotherapy 3
Neurological symptoms
 20
 9
TKI, tyrosine kinase inhibitor.
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standard for NM diagnosis, cytological detection of malig-
nant cells in CSF, is highly specific for NM, but its sensitivity
is 50 to 60% in patients with autopsy-proven leptomeningeal
tumors.4,5 This is because meningeal dissemination is com-
monly localized to the brain, yet CSF examination is typically
performed by lumbar puncture.3 Another reason is that CSF
specimens frequently contain so few morphologically recog-
nizable malignant cells that even the most experienced cytol-
ogists are unable to render a definitive diagnosis. From a
clinical point of view, a more sensitive method to diagnose
NM is needed.
In this study, we analyzed CSF from patients with lung
cancer suspected of having NM using a direct sequencing
method targeting EGFR mutations. Choong et al.18 reported
that EGFR mutations of malignant cells were detected in a
patient with lung cancer with NM using CSF, whereas the
EGFR sequence of normal leukocytes isolated from the CSF
was wild type. We hypothesized that EGFR mutations are
tumor specific for the detection of malignant cells.
When analyzing CSF, we used CSF supernatants as
material. Kimura et al.15 showed that detecting EGFR muta-
FIGURE 1. A, Enhanced axial T1-weighted MRI shows
thickening of the dura-arachnoid of the right cerebellum
hemisphere (arrows) and pia-subarachnoid space enhance-
ment invaginating into the sulci of the cerebellum. B, Cytol-
ogy results from CSF reveal adenocarcinoma (Papanicolaou
stain). C, Direct sequencing shows L858R point mutation in
CSF. MRI, magnetic resonance imaging; CSF, cerebrospinal
fluid.
TABLE 2. Mutations in the Tyrosine Kinase Domain of the EGFR Gene in Cerebral Spinal Fluid and Tumor by Direct DNA Sequencing
No. Gender Age Pathology
Initial
Stage
Prior
Treatment
Neurological
Symptoms
CSF
Cytology
No. of
Cells in
CSF (/3 L)
Direct Sequence Tumor
Biopsy
SiteCSF Tumor
1 M 56 Ad IV Chemo  I 1 N. D. WT Bone
2 F 40 Ad IV —  I 2 L858R, V843I NA
3 F 68 Ad IV —  I 9 N. D. Ex18 (T2158C) Lung
4 F 70 Ad IV —  I 3 N. D. L858R Med. LN
5 M 42 Ad IV Chemo  I 2 E746-A750 del WT Med. LN
6 F 60 Ad IV —  I 1 E746-A750 del E746-A750 del SCLN
7 F 74 Ad IV Chemo  I 1 N. D. WT Lung
8 M 65 Ad IV Chemo and TKI  I 1 N. D. L858R Med. LN
9 F 66 Ad IV TKI  IIa 53 (traumatic) N. D. L858R Lung
10 M 67 Ad IV Chemo  IIa 0 N. D. E746-A750 del Bone
11 M 60 Ad IIIA Ope. and chemo  IIa 2 L747-T751 del WT Lung
12 M 71 Ad IV Chemo  IIa 3 N. D. NA
13 M 64 Ad IIIB Chemo  IIa 9 E746-A750 del WT Lung
14 F 68 Ad IV TKI  IIa 2 N. D. L747-A750 del Lung
15 M 61 Ad IV Chemo and TKI  IIa 1 N. D. WT Med. LN
16 F 70 Ad IV Chemo  IIb 1 N. D. WT Lung
17 F 82 Ad IIA Ope. and chemo  IV 8 L747-E749 del A750P WT Lung
18 M 70 Ad IV Chemo  V 13 L747-S752 del P753S NA
19 F 70 Ad IV Chemo  V 52 WT NA
20 F 64 Ad IV TKI  V 80 L858R NA
21 M 56 Ad IV TKI  V 10 L747-E749 del A750P NA
22 M 63 Ad IV TKI  V 9 L747-E749 del A750P NA
23 M 55 Ad IV —  V 2 WT WT Med. LN
24 M 68 Ad IV Chemo  V 548 WT NA
25 F 78 Ad IV —  V 3 L858R NA
26 M 67 Ad IV —  V 6 WT E746-A751 del (insA) Med. LN
27 F 60 Ad IV —  V 11 L858R L858R, T790M Lung
28 F 63 Ad IIIB Ope.  V 23 E746-A750 del E746-A750 del Lung
29 M 61 Ad IIIB Ope and chemo  V 2 WT L858R, K860I Lung
EGFR, epithelial growth factoe receptor; Ad, adenocarcinoma; Chemo, chemotherapy; TKI, tyrosine kinase inhibitor; Ope, operation; CSF, cerebrospinal fluid; ND, none
detected; NA, not available; Med LN, mediastinal lymph node; SCLN, supraclavicular lymph node.
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tions in a pleural effusion from patients with NSCLC is useful
for predicting the response to gefitinib. They were able to
extract DNA from the supernatant of centrifuged pleural
effusions to determine the mutation status of EGFR using a
direct sequencing method, even though the concentration of
the extracted DNA specimens was in most cases below the
concentration detectable by spectrophotometry. Similarly,
using the supernatant of CSF to extract DNA might be
important to reduce the proportion of wild-type EGFR DNA
in samples containing a mixture of tumor and normal cells
and to detect small amounts of mutated EGFR DNA in tumor
cells in CSF. In our analysis, mutated EGFR DNA was
detected in CSF of 13 (45%) of 29 patients. This DNA may
be present in nuclear debris derived from dead cells or even
as soluble DNA released from dead tumor cells.
In this study, EGFR mutations in CSF were detected in
5 of 16 patients with class I to IIb CSF cytology. Kanaji et
al.19 reported that mutant EGFR RNA was detected in CSF
from a patient with lung cancer suspected of NM, despite
negative CSF cytology; and by consequent CSF cytology,
diagnosis of NM was established. Their report suggests that
detecting mutant EGFR RNA in CSF is a useful method
to diagnosis NM at early stage. In our study, all five patients
died within 27 to 302 days of their lumbar puncture exami-
nation. Although in some patients NM was later suspected, a
second lumbar puncture was not performed because of their
poor general condition. Detecting mutant EGFR RNA in CSF
might be better to diagnose NM at early stage than mutant
EGFR DNA, but there are no data comparing mutant EGFR
DNA with RNA. Further studies are needed to clarify the
clinical significance of detecting mutant EGFR DNA in CSF.
Curiously, in this study, there was discordance of
EGFR status between CSF and primary or metastatic lesions
in seven patients. In four (patient nos. 5, 11, 13, and 17) of the
seven patients, EGFR mutations were detected in the CSF,
but not in the tumors. In all four patients, chemotherapy had
been provided before CSF examination. In another two pa-
tients (nos. 26 and 29) with EGFR mutant tumors, EGFR
mutation was not detected in CSF despite positive CSF
cytology. The last patient (no. 27) had an L858R point
mutation in both the primary tumor and the CSF. Neverthe-
less, a T790M mutation, associated with resistance to EGFR-
TKI, was found in the primary tumor, but not in the CSF.
There are two reports regarding discordance of EGFR muta-
tion status between primary tumors and metastases including
those of lymph nodes, brain, bone, skin, soft tissue, intestine,
and liver.20,21 Two patterns of discordance were shown in
those reports. One is that mutant EGFR primary tumors lose
the mutation when they become metastatic. The other is that
wild-type EGFR primary tumors gain the mutation when they
become metastatic. Nevertheless, there have been no reports
to compare the EGFR DNA status between tumors and CSF
in patients with lung cancer, as examined in this study. These
findings suggest that EGFR mutations may change during
metastases into CSF after diagnosis of the primary tumors.
Another reason of discordance of EGFR status between CSF
and primary or metastatic lesions might be because of the
limitation of sensitivity to detect EGFR mutation by direct
sequencing.
With the development of anti-EGFR TKI therapy,
EGFR mutation status has been proposed to guide patient
selection. Moreover, there are several reports that EGFR TKI
is effective for NM in patients with mutant EGFR
NSCLC.18,22,23 Nevertheless, it remains unclear whether
EGFR TKI is effective for patients in whom EGFR status is
different between tumors and CSF. In this study, EGFR TKI
was administered to 7 of 12 patients with cytologically
confirmed NM. In two of seven patients with EGFR mutant
tumors, no EGFR mutations were detected in CSF despite
positive CSF cytology. For these two patients (nos. 26 and
29), gefitinib was administered with a combination of whole
brain radiation and intra-CSF chemotherapy using thiotepa,
an alkylating ethyleneimine compound. One patient (no. 26)
died of pneumonia 74 days after diagnosis of NM. The other
patient (no. 29) is still alive 7 months after diagnosis of NM
with diminishing malignant cells in the CSF. Nevertheless, at
this time, MRI of the spinal cord showed relapse. In contrast,
there are four patients in whom EGFR mutation was detected
only in the CSF, but not in tumors. In one of four patients,
gefitinib was administered, but the patient (no. 17) died after
117 days. One patient (no. 27) had an L858R point mutation
in both the primary tumor and the CSF. Nevertheless, a
T790M mutation, associated with resistance to EGFR-TKI,
was found in the primary tumor, but not in the CSF. This
patient received gefitinib with a combination of whole brain
radiation and intra-CSF chemotherapy using thiotepa. Tho-
racic lesions diminished, but malignant cells in the CSF
remained and neurological symptoms worsened. She died
192 days after CSF examination. Ruppert et al.24 reported a
patient with lung cancer with NM, in whom a secondary
T790M mutation, associated with resistance to EGFR-TKI,
was found in a liver biopsy, but not in the CSF. Erlotinib was
reintroduced and produced a quick neurological improve-
ment, even though the extracranial disease remained resistant
to erlotinib. In this patient, erlotinib was effective for the
neurological disorder. The discrepancy between this case and
ours may be partly explained by the difference in effective-
ness for NM between gefitinib and erlotinib. In some patients,
EGFR mutation status differs between the tumors and the
CSF. Although gefitinib was administered to some of the
patients in this study, further studies are needed to clarify
the effectiveness of TKI in these patients. Along with the
development of anti-EGFR TKI therapy, EGFR mutation
analysis is widely used to determine patient selection. Nev-
ertheless, in our study, we reported cases in which EGFR
status was different between the tumors and the CSF. Anal-
ysis of EGFR mutations only in tumors might be inadequate
for planning the use of TKI for NSCLC.
CONCLUSIONS
EGFRmutations, suggesting the existence of malignant
cells, were detected in the CSF, even in patients with NSCLC
with negative cytological results. EGFRmutations in the CSF
do not always reflect the same status as in primary or
metastatic lesions.
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